Age of Onset of Receptor Tyrosine Kinase Fusions Drives Distinct Biologic Outcomes in Thyroid Cancer

被引：4
|
作者：
Fagin, James A. [1 ,2 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, Dept Med, 1275 York Ave, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10065 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 10期
关键词：
REARRANGEMENTS; CARCINOMA; CHILDREN;
D O I：
10.1200/JCO.21.02864
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1124 / +
页数：4
相关论文
共 50 条
  • [1] Diagnostic approach of tumors with neurotrophic tropomyosin receptor tyrosine kinase gene fusions
    Lippai Zoltan
    Sapi Zoltan
    ORVOSI HETILAP, 2020, 161 (41) : 1753 - 1763
  • [2] Loss of progesterone receptor is associated with distinct tyrosine kinase profiles in breast cancer
    Tahiri, Andliena
    Tekpli, Xavier
    Satheesh, Somisetty, V
    DeWijn, Rik
    Luders, Torben
    Bukholm, Ida R.
    Hurtado, Antoni
    Geisler, Juergen
    Kristensen, Vessela N.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (03) : 585 - 598
  • [3] Mechanism of immune escape mediated by receptor tyrosine kinase KIT in thyroid cancer
    Luo, Zhen
    Xu, Jin
    Xu, Dayong
    Xu, Jiaojiao
    Zhou, Rongjun
    Deng, Keping
    Chen, Zheng
    Zou, Fang
    Yao, Libo
    Hu, Yuqin
    IMMUNITY INFLAMMATION AND DISEASE, 2023, 11 (07)
  • [4] Treatment outcomes of differentiated thyroid cancer with distant metastasis improve by tyrosine kinase inhibitors
    Iwasaki, Hiroyuki
    Yamazaki, Haruhiko
    Takasaki, Hirotaka
    Suganuma, Nobuyasu
    Sakai, Rika
    Nakayama, Hirotaka
    Hatori, Shinsuke
    Toda, Soji
    Masudo, Katsuhiko
    ONCOLOGY LETTERS, 2019, 17 (06) : 5292 - 5300
  • [5] Perspectives on the use of tyrosine kinase inhibitors in thyroid cancer
    Quintana-Quintana, Miguel
    Orta-Cortes, David
    Tletlepantzin-Apartado, Miguel A.
    Toriz-Hernandez, Jose A.
    Mendez-Calderillo, Viridiana
    Paredes-Fernandez, Sandra R.
    Alvarez-Dominguez, Tania P.
    Mora-Perez, Josue
    GACETA MEXICANA DE ONCOLOGIA, 2020, 19 (01): : 24 - 32
  • [6] AN EXPANDING CLASS IN THE TREATMENT OF THYROID CANCER: TYROSINE KINASE INHIBITORS
    Dobrescu, R.
    Badiu, C.
    ACTA ENDOCRINOLOGICA-BUCHAREST, 2015, 11 (04) : 536 - 539
  • [7] Targeting RET Receptor Tyrosine Kinase Activation in Cancer
    Phay, John E.
    Shah, Manisha H.
    CLINICAL CANCER RESEARCH, 2010, 16 (24) : 5936 - 5941
  • [8] Tyrosine kinase alterations in colorectal cancer with emphasis on the distinct clinicopathological characteristics
    Okano, Soh
    Yamashiro, Yuya
    Onagi, Hiroko
    Sasa, Keita
    Hayashi, Takuo
    Takahashi, Makoto
    Sugimoto, Kiichi
    Sakamoto, Kazuhiro
    Yao, Takashi
    Saito, Tsuyoshi
    HISTOPATHOLOGY, 2023, 83 (05) : 733 - 742
  • [9] The role of oestrogen receptor α in human thyroid cancer: contributions from coregulatory proteins and the tyrosine kinase receptor HER2
    Kavanagh, Dara O.
    McIlroy, Marie
    Myers, Eddie
    Bane, Fiona
    Crotty, Thomas B.
    McDermott, E.
    Hill, Arnold D.
    Young, Leonie S.
    ENDOCRINE-RELATED CANCER, 2010, 17 (01) : 255 - 264
  • [10] Follicular Variant of Papillary Thyroid Cancer Encapsulated, Nonencapsulated, and Diffuse: Distinct Biologic and Clinical Entities
    Gupta, Sachin
    Ajise, Oluyomi
    Dultz, Linda
    Wang, Beverly
    Nonaka, Daisuke
    Ogilvie, Jennifer
    Heller, Keith S.
    Patel, Kepal N.
    ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2012, 138 (03) : 227 - 233
12345